TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03383510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Climate friendly diet
Description: Participants in the 'Climate friendly' group will be assigned a diet generating low emissions of greenhouse gases. The target is to reduce the participants' diet-related carbon dioxide equivalents (CO2e) to 2.5 kg per person and day, which is approximately a reduction by 50% compared the average CO2e, according to a previous study on diet-related CO2e in Sweden. The participants will be instructed to reduce their consumption of beef and dairy products and increase their consumption of plant-foods i.e. fruits, vegetables, legumes and whole-grain cereals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic diet
Description: Participants in the 'Organic group' will be assigned an organic diet with very low, or no, content of pesticides. The participants will be instructed to replace at least 50% of their food intake with organic foods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Climate friendly and organic diet
Description: The participants in the 'Climate friendly and organic diet group' will be assigned a combination of a climate friendly and organic diet generating low emissions of greenhouse gas and having very low levels of pesticides. The target is to reduce the participants' diet-related CO2e to 2.5 kg per person and day. The participants will be instructed to replace at least 50% of their food intake with organic products.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group (Control diet)
Description: A conventional diet according to the Nordic Nutrition Recommendations (NNR). The participants will get information about the present dietary guidelines and how they can adhere to the guidelines, for example, by implementing the plate model for meals and learning about recommended levels of intake of macronutrients, micronutrients, fiber and energy.
Study: NCT04168099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Description: Cefotaxime IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemifloxacin
Description: Gemifloxacin oral
Study: NCT01166204

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study: NCT01966913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICE chemotherapy regimen
Description: Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals, Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance, Ifosfamide, 2400 mg/m²/d, For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle
Study: NCT00829114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETHINYL ESTRADIOL AND LEVOGESTREL
Description: 30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETHINYL ESTRADIOL AND LEVOGESTREL
Description: 30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
Study: NCT00828009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy is given 5 days a week for 6½ weeks during concomitant chemoradiotherapy
Study: NCT02360904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: The intervention will consist of 12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training. Classes will be conducted at the Beth Israel Comprehensive Cancer Center in a closed-group format, and will be offered twice a week. Yoga mats will be provided for each patient. The maximum number of patients attending each class will be 12. The classes will combine physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). We would also encourage patient to practice yoga at home and keep a diary.
Study: NCT01529424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS apoC-III Rx
Description: Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS apoC-III Rx
Description: Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS apoC-III Rx
Description: Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose 3
Study: NCT03751215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: During cataract surgery the patient is implanted with the monofocal IOL Clareon in one eye and the monofocal IOL AcrySof in the contralateral eye
Study: NCT02360904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The intervention will consist of 12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training. Classes will be conducted at the Beth Israel Comprehensive Cancer Center in a closed-group format, and will be offered twice a week. Yoga mats will be provided for each patient. The maximum number of patients attending each class will be 12. The classes will combine physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). We would also encourage patient to practice yoga at home and keep a diary.
Study: NCT05371340

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin (500 mg)
Description: Once-daily 500 mg Quercetin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (500 mg)
Description: Once-daily 500 mg methylcellulose 9E4M)
Study: NCT01347931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIOV System
Description: Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.
Study: NCT00882531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: 0.25 mg/kg, 1 per day, 4 month of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03325166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02727348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic with or without femoral block
Description: Sciatic with or without femoral block performed either with ultrasound and/or nerve stimulator on the patient with 3mg/kg of ropivacaine
Study: NCT02519205

Intervention type: OTHER
Intervention: Survey
Study: NCT04269876

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marine Lipid Oil Concentrate
Description: Marine Lipid Oil Concentrate softgels

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement
Description: Dietary Supplement capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo softgels

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT00549445

Intervention type: DRUG
Intervention: Azithromycin
Description: 250 mg daily

Intervention type: DRUG
Intervention: Placebo
Description: Daily
Study: NCT00851786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX
Description: Subcutaneous injection of 0.65 mL of ZOSTAVAX at Day 0 and Week 6

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of 0.65 mL of placebo at Day 0 and Week 6
Study: NCT01524146

Intervention type: PROCEDURE
Intervention: Photodynamic Therapy
Description: PDT is a therapeutic approach that specifically targets neoplastic cells.~• PDT involves three components:~1. Photofrin or a similar Photosensitizing agent that would be injected 3 days prior to laser activation of the agent.~2. Laser System - For laser energy delivery to activate the photosensitizing agent and induce tumor tissue necrosis~3. Optic Fiber - Delivery Fiber used along with the laser system to achieve Photoactivation of the photosensitizing agent.~Technique:~Subjects will be injected with Photofrin or similar drug. 3 days post injection, the subject will receive photodynamic therapy during an Endoscopic Retrograde cholangiopancreatography (ERCP) procedure. Subject will undergo stenting as part of standard of care procedure post photodynamic therapy.~Subject may undergo multiple photodynamic therapy sessions with a gap of at least 3 months.
Study: NCT03963843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided ICBT
Description: An 8-week internet- delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a health educator with experience delivering ICBT will provide support by email once a week. The health educator will spend approximately 15 minutes per week/per client.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SCI rehabilitation mental health education
Description: Participants will receive information provided to SCI patients in usual care at specialized SCI rehabilitation units (the Spinal Cord Injury Rehabilitation Evidence (SCIRE) Community handouts available at: https://scireproject.com/community/handouts/). The lessons will include information on spinal cord injury rehabilitation: 1)spinal cord injury basics, 2)mental health after SCI, 3)pain after SCI, 4)understanding rehabilitation 5)summary of lessons through an online platform over 8 weeks. A health educator will check in with participants once a week to answer any content related questions. The health educator will spend approximately 15 minutes per week/per client.
Study: NCT02865655

Intervention type: PROCEDURE
Intervention: Hysteroscopic
Study: NCT02987270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: Dihydroartemisinin-piperaquine is an antimalarial in the artemisinin-based combination therapy class of drugs. It is the Kenya Ministry of Health second-line treatment for malaria in Kenya.
Study: NCT00781833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio Frequency Microstimulator
Description: Implantable peripheral muscle microstimulator, delivering controlled pulsatile stimulation to femoral nerves for knee extension and peroneal nerves for dorsiflexion.
Study: NCT02663622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efprezimod alfa
Description: Acute GVHD prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efprezimod alfa
Description: Acute GVHD prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efprezimod alfa
Description: Acute GVHD prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Acute GVHD prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Acute GVHD prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Acute GVHD prophylaxis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Acute GVHD prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Acute GVHD prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Acute GVHD prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Acute GVHD prophylaxis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tacrolimus
Description: Acute GVHD prophylaxis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml saline IV infusion.
Study: NCT03020927

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reciprocal Imitation Training (Therapist-Delivered)
Description: Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reciprocal Imitation Training (Therapist + Parent Delivered)
Description: Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills, using a combination of therapist-delivered intervention and parent training to deliver intervention in the home setting.
Study: NCT01825967

Intervention type: OTHER
Intervention: C-reactive protein
Description: measured C-reactive protein in all patients with acute diverticulitis
Study: NCT00653380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Monohydrate
Description: Capsules, 100 mg, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monodox
Description: Capsules, 100 mg, single-dose
Study: NCT02112292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrahydrocannabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrahydrocannabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrahydrocannabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrahydrocannabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrahydrocannabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrahydrocannabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04479202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Patients in the intervention group received berberine daily, regardless of gastrointestinal symptoms.If the patient has a serious drug-related adverse event, the drug will be discontinued and the patient will be excluded from the study.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Montmorrillonite
Description: Patients in the control group were routinely not given special treatment.However, if the patient has diarrhea symptoms, montmorillonite powder should be given orally.
Study: NCT00932321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone Acetate/Ethinyl Estradiol 24 Days
Description: One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethindrone Acetate /Ethinyl Estradiol 21 Days
Description: One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets
Study: NCT01918956

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PURETHAL Birch, 20.000 AUM/ml
Description: comparison of different up-dosing regimes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PURETHAL Birch, 20.000 AUM/ml
Description: comparison of different up-dosing regimes
Study: NCT02727348

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anaesthesia
Description: Spinal anaesthesia with up to 3mls of 0.5% bupivacaine
Study: NCT03042234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Insulin-Resistant
Description: High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
Study: NCT00559247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032 or Placebo
Description: Oral, Once daily, Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032 or Placebo
Description: Oral, Once daily, Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032 or Placebo
Description: Oral, Once daily, Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032 or Placebo
Description: Oral, Once daily, Single Dose
Study: NCT02606331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: Corticotomy cuts will be performed by this technique.
Study: NCT03042234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Insulin-Resistant
Description: High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Insulin-Sensitive
Description: High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Insulin-Sensitive
Description: High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
Study: NCT03460587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The Telerehabilitation system will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
Study: NCT02606331

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ER:YAG laser
Description: Corticotomy cuts will be performed by this technique.
Study: NCT02775916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDZ173

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00163020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-alpha-hydroxyprogesterone caproate injectable
Description: 250mg of 17-alpha-hydroxyprogesterone caproate (+ preservatives) injectable weekly starting as early as 19wks gestation until 34.0wks gestation of delivery which ever comes first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
Study: NCT02814175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate (MTX)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate (MTX)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate (MTX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate (MTX)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate (MTX)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab (ADA)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab (ADA)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab (ADA)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab (ADA)
Study: NCT02501499

Intervention type: OTHER
Intervention: Breastfeeding Buddies
Description: a 2 hour breastfeeding workshop and if mother chooses, she is matched with a buddy who will contact her and offer breastfeeding support
Study: NCT03556709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill Ankle Robot Training
Description: This intervention employs the use of an adaptive ankle robot control system, during treadmill walking, over a 6-week intervention period.
Study: NCT01286740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/RPV/TDF
Description: Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
Study: NCT05456971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Art Filler Volume
Description: Midface correction with injectable hyaluronic acid based-filler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Art Filler Lips
Description: Lipscorrection with injectable hyaluronic acid based-filler
Study: NCT00952341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Day 1: Oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Oral aprepitant 80 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to aprepitant
Description: Day 1: Placebo to oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Placebo to oral aprepitant 80 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexamethasone
Description: Day 1: Oral dexamethasone 10.5 mg prior to administration of cisplatin; Days 2, 3, and 4: Oral dexamethasone 7.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: Day 1: IV granisetron 3 mg prior to administration of cisplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: granisetron
Description: Day 1: IV granisetron 3 mg prior to administration of cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Day 1: oral dexamethasone 6 mg prior to the administration of cisplatin; Days 2 and 3: oral dexamethasone 3.75 mg
Study: NCT00024089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib